These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 1700902

  • 1. Functional relationship between cyclic AMP-dependent protein phosphorylation and platelet inhibition.
    Siess W, Lapetina EG.
    Biochem J; 1990 Nov 01; 271(3):815-9. PubMed ID: 1700902
    [Abstract] [Full Text] [Related]

  • 2. Cyclic AMP-dependent phosphorylation of glycoprotein Ib inhibits collagen-induced polymerization of actin in platelets.
    Fox JE, Berndt MC.
    J Biol Chem; 1989 Jun 05; 264(16):9520-6. PubMed ID: 2542312
    [Abstract] [Full Text] [Related]

  • 3. Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E1 on human platelet function.
    Fisher CA, Kappa JR, Sinha AK, Cottrell ED, Reiser HJ, Addonizio VP.
    J Lab Clin Med; 1987 Feb 05; 109(2):184-90. PubMed ID: 2433373
    [Abstract] [Full Text] [Related]

  • 4. Identification of glycoprotein Ib beta as one of the major proteins phosphorylated during exposure of intact platelets to agents that activate cyclic AMP-dependent protein kinase.
    Fox JE, Reynolds CC, Johnson MM.
    J Biol Chem; 1987 Sep 15; 262(26):12627-31. PubMed ID: 3040761
    [Abstract] [Full Text] [Related]

  • 5. Endogenous ADP prevents PGE1-induced tyrosine dephosphorylation of focal adhesion kinase in thrombin-activated platelets.
    Vostal JG, Shafer B, Mondoro TH, Fratantoni JC.
    Biochim Biophys Acta; 1996 Nov 08; 1314(1-2):1-12. PubMed ID: 8972712
    [Abstract] [Full Text] [Related]

  • 6. Phosphorylation of rap1B by protein kinase A is not involved in platelet inhibition by cyclic AMP.
    Siess W, Grünberg B.
    Cell Signal; 1993 Mar 08; 5(2):209-14. PubMed ID: 7684600
    [Abstract] [Full Text] [Related]

  • 7. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
    Maurice DH, Haslam RJ.
    Mol Pharmacol; 1990 May 08; 37(5):671-81. PubMed ID: 2160060
    [Abstract] [Full Text] [Related]

  • 8. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
    Merritt JE, Hallam TJ, Brown AM, Boyfield I, Cooper DG, Hickey DM, Jaxa-Chamiec AA, Kaumann AJ, Keen M, Kelly E.
    Br J Pharmacol; 1991 Jan 08; 102(1):251-9. PubMed ID: 1710526
    [Abstract] [Full Text] [Related]

  • 9. Effects of activation of protein kinase C on the agonist-induced stimulation and inhibition of cyclic AMP formation in intact human platelets.
    Williams KA, Murphy W, Haslam RJ.
    Biochem J; 1987 May 01; 243(3):667-78. PubMed ID: 2444206
    [Abstract] [Full Text] [Related]

  • 10. Characterization of prostaglandin and thromboxane receptors expressed on a megakaryoblastic leukemia cell line, MEG-01s.
    Watanabe T, Yatomi Y, Sunaga S, Miki I, Ishii A, Nakao A, Higashihara M, Seyama Y, Ogura M, Saito H.
    Blood; 1991 Nov 01; 78(9):2328-36. PubMed ID: 1718495
    [Abstract] [Full Text] [Related]

  • 11. Novel mechanism of heterologous desensitization of adenylate cyclase: prostaglandins bind with different affinities to both stimulatory and inhibitory receptors on platelets.
    Ashby B.
    Mol Pharmacol; 1990 Jul 01; 38(1):46-53. PubMed ID: 1695318
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Platelet rap1B phosphorylation is a sensitive marker for the action of cyclic AMP- and cyclic GMP-increasing platelet inhibitors and vasodilators.
    Grünberg B, Kruse HJ, Negrescu EV, Siess W.
    J Cardiovasc Pharmacol; 1995 Apr 01; 25(4):545-51. PubMed ID: 7596121
    [Abstract] [Full Text] [Related]

  • 14. Effects of TRK-100, a stable prostacyclin analogue, on regulation of cyclic AMP metabolism in platelets.
    Nogimori K, Kajikawa N, Nishio S, Yajima M.
    Prostaglandins; 1989 Feb 01; 37(2):205-12. PubMed ID: 2543034
    [Abstract] [Full Text] [Related]

  • 15. Developmental Differences in Platelet Inhibition Response to Prostaglandin E1.
    Palma-Barqueros V, Torregrosa JM, Caparrós-Pérez E, Mota-Pérez N, Bohdan N, Llanos MDC, Begonja AJ, Sola-Visner M, Vicente V, Teruel-Montoya R, Rivera J, Ferrer-Marín F.
    Neonatology; 2020 Feb 01; 117(1):15-23. PubMed ID: 31786577
    [Abstract] [Full Text] [Related]

  • 16. Prostacyclin inhibits platelet aggregation induced by phorbol ester or Ca2+ ionophore at steps distal to activation of protein kinase C and Ca2+-dependent protein kinases.
    Siess W, Lapetina EG.
    Biochem J; 1989 Feb 15; 258(1):57-65. PubMed ID: 2494992
    [Abstract] [Full Text] [Related]

  • 17. 6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent.
    Miller OV, Aiken JW, Shebuski RJ, Gorman RR.
    Prostaglandins; 1980 Aug 15; 20(2):391-400. PubMed ID: 6251513
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Impaired responsiveness of platelets from patients with stable angina pectoris to antiaggregating and cyclicAMP-elevating effects of prostaglandin E1.
    Chirkov YY, Chirkova LP, Sage RE, Horowitz JD.
    J Cardiovasc Pharmacol; 1995 Jun 15; 25(6):961-6. PubMed ID: 7564342
    [Abstract] [Full Text] [Related]

  • 20. Demonstration of a novel circulating anti-prostacyclin receptor antibody.
    Kahn NN, Bauman WA, Sinha AK.
    Proc Natl Acad Sci U S A; 1997 Aug 05; 94(16):8779-82. PubMed ID: 9238054
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.